
    
      In this Phase 3, double blind, vehicle controlled study, patients will be admitted into this
      multi center, double blind, randomized, vehicle controlled, parallel group pivotal study only
      after a written informed consent has been obtained and after all inclusion/exclusion criteria
      have been met. Male and female patients at least 18 years of age with moderate or severe
      papulopustular rosacea will be eligible for enrollment for daily treatment with S5G4T-1 or
      its vehicle for 12 weeks.
    
  